ClinicalTrials.gg
CompletedNCT00322153Updated Sep 16, 2010Results posted

A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease

A Phase 3 interventional study of memantine ER and Placebo in Dementia of the Alzheimer's Type, sponsored by Forest Laboratories. Completed at 83 sites in 4 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2010-09-16.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
677
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.

Enrollment
Largest of 34
677 · median 90
Started
2005
with 3 others
Phase 3
8 of 34
none open now
Registered
6th of 34
by date
Lead sponsor
4 of 34
Forest Laboratories

Among the 34 studies testing memantine in Alzheimer Disease, this one has the largest enrollment, is one of 4 that started in 2005, is one of 8 in phase 3, and was the 6th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About memantine

Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing memantine in Alzheimer Disease, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).

Read the detailed description

Memantine is a therapeutic agent that represents a unique class of Alzheimer's disease (AD) treatment options. A once daily (QD) dosing regimen in an AD population would simplify administration for the caregiver. The purpose of this study is to evaluate the safety and efficacy of modified release memantine taken once daily in outpatients with moderate-to-severe AD on a concurrent AChEI.

03

Conditions studied

  • Dementia of the Alzheimer's Type

Browse trials for

Keywords

  • memantine
  • Alzheimer's disease
  • moderate to severe Alzheimer's disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory patients aged >/= 50 years
  • Diagnostic evidence of probable Alzheimer's disease consistent with criteria from the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and the , Fourth Edition, Text Revision (DSM-IV-TR)
  • Confirmatory magnetic resonance imaging (MRI) or computed tomographic (CT) scan within the prior 12 months.
  • (MMSE) scores >/= 3 and \</= 14 at Screening (Visit 1) and Baseline (Visit 2)
  • Ongoing daily acetylcholinesterase inhibitor (AChEI) therapy at a stable dose for at least 3 months prior to Screening (Visit 1). It is preferred that patients continue to receive the same AChEI therapy for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with a modified Hachinski Ischemia Score greater than 4 at Screening.
  • Patients who have taken memantine within one month of Screening (Visit 1)
  • Patients who have a known to memantine, neramexane, rimantadine, or amantadine.
  • Patients whose AChEI therapy is likely to be interrupted or discontinued during the course of the study.
  • Patients who are receiving therapy with more than one AChEI.
  • Patients with computed tomography (CT) or magnetic resonance imaging (MRI) evidence of hydrocephalus, stroke, a space-occupying lesion, cerebral infection, or any central nervous system disease other than Alzheimer's disease.
  • Patients with a Axis I disorder other than Alzheimer's disease, including amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, or post-traumatic stress disorder.
  • Patients who, in the clinician's judgement, are likely to be placed in a nursing home within the next 6 months.
  • Patients who had evidence of other neurological disorders that included, but were not limited to, stroke, Parkinson's disease, seizure disorder, or head injury with loss of consciousness within the prior 5 years
  • Patients who had dementia that was complicated by other organic disease
  • Patients who had dementia complicated by the presence of predominant delusions
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
677 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Oral administration, once daily.

    Drug: Placebo

  • Active comparator
    Memantine ER

    28mg, once daily. Oral administration for 24 weeks.

    Drug: memantine ER

Interventions

  • 28mg(7mg capsules) once daily and oral administration for 24 weeks.

    Also known as: Namenda XR

  • DrugPlacebo

    Matching placebo oral administration once daily.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF)

    The SIB was developed for the evaluation of cognitive function in patients with more advanced dementia, and evaluates the areas of memory, language, praxis, orientation, and attention. The SIB test items consist of simple, one-step commands presented with gestural cues that are repeated if necessary. The test contains 51 items, and the range of possible scores is 0 to 100 (with 0 being the worst result). The SIB has been shown to be a valid and reliable instrument sensitive to longitudinal change.

    Time frame: Baseline to week 24

  2. Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus) at Week 24 (LOCF)

    The CIBIC-Plus is a measure of an overall clinical effect and is based on a comprehensive evaluation at Baseline and later visits of four domains: general (overall clinical status), functional (including activities of daily living), cognitive, and behavioral. A skilled clinician interviews the patient, and includes information supplied by a knowledgeable caregiver. The CIBIC-Plus is a rating of the patient's global status relative to Baseline, ranging from a score of 1, indicating "marked improvement" to a score of 4, indicating "no change" to a score of 7, indicating "marked worsening."

    Time frame: Week 24

Secondary outcomes

  1. Change From Baseline in the 19-Item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) Scale at Week 24 (LOCF)

    The ADCS-ADL19 modified inventory consists of 19 items used to measure the functional capabilities of patients with moderate to severe dementia. Each activity-of-daily-living (ADL) item comprises a series of hierarchical subquestions ranging from the highest level of independent performance to complete loss of ability to perform the ADL Inventory. The inventory is performed by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks. Response range is 0 (total disability) to 54 (total independence).

    Time frame: Baseline to week 24

07

Results

Posted Sep 16, 2010

Participant flow

The recruitment period was from May 20, 2005 to April 18th, 2007 at 83 study centers in four countries (23 in Argentina, 11 in Chile, 11 in Mexico, and 38 in the US)

Participant flow — Overall Study
MilestonePlaceboMemantine ER
Started335342
Safety population335341
Completed272273
Not completed6369
Withdrew: Adverse event2134
Withdrew: Protocol violation614
Withdrew: Withdrawal by subject1810
Withdrew: Lack of efficacy83
Withdrew: Lost to follow-up54
Withdrew: Withdrawn for other reasons54

Outcome measures

PrimaryChange From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF)

The SIB was developed for the evaluation of cognitive function in patients with more advanced dementia, and evaluates the areas of memory, language, praxis, orientation, and attention. The SIB test items consist of simple, one-step commands presented with gestural cues that are repeated if necessary. The test contains 51 items, and the range of possible scores is 0 to 100 (with 0 being the worst result). The SIB has been shown to be a valid and reliable instrument sensitive to longitudinal change.

Time frame:
Baseline to week 24
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF)
Units on a scalePlaceboMemantine ER
Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF)-0.4 ± 0.652.2 ± 0.65
Statistical analysis
  • Placebo vs Memantine ER · ANCOVA · p = 0.001 · Mean difference (final values): 2.6 · 95% CI 1.0 to 4.2Least-squares mean (-0.4 in placebo and 2.2 in memantine ER) are controlled for center and adjusted for SIB baseline value.
PrimaryClinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus) at Week 24 (LOCF)

The CIBIC-Plus is a measure of an overall clinical effect and is based on a comprehensive evaluation at Baseline and later visits of four domains: general (overall clinical status), functional (including activities of daily living), cognitive, and behavioral. A skilled clinician interviews the patient, and includes information supplied by a knowledgeable caregiver. The CIBIC-Plus is a rating of the patient's global status relative to Baseline, ranging from a score of 1, indicating "marked improvement" to a score of 4, indicating "no change" to a score of 7, indicating "marked worsening."

Time frame:
Week 24
Reported as:
Mean · Units on a scale
Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus) at Week 24 (LOCF)
Units on a scalePlaceboMemantine ER
Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus) at Week 24 (LOCF)4.1 ± 0.073.8 ± 0.07
Statistical analysis
  • Placebo vs Memantine ER · Cochran-Mantel-Haenszel · p = 0.008
SecondaryChange From Baseline in the 19-Item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) Scale at Week 24 (LOCF)

The ADCS-ADL19 modified inventory consists of 19 items used to measure the functional capabilities of patients with moderate to severe dementia. Each activity-of-daily-living (ADL) item comprises a series of hierarchical subquestions ranging from the highest level of independent performance to complete loss of ability to perform the ADL Inventory. The inventory is performed by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks. Response range is 0 (total disability) to 54 (total independence).

Time frame:
Baseline to week 24
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the 19-Item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) Scale at Week 24 (LOCF)
Units on a scalePlaceboMemantine ER
Change From Baseline in the 19-Item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) Scale at Week 24 (LOCF)-1.7 ± 0.44-1.0 ± 0.44
Statistical analysis
  • Placebo vs Memantine ER · ANCOVA · p = 0.177 · Mean difference (final values): 0.7 · 95% CI -0.3 to 1.8Least-squares mean (-1.7 in placebo and -1.0 in memantine ER) are controlled for center and adjusted for ADCS-ADL19 baseline value.

Adverse events

Collected over Occurring on or after the date of the first dose of double-blind study medication and within 30 days of the date of last dose of double-blind study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—21/335 (6.3%)70/335 (20.9%)
Memantine ER—28/341 (8.2%)67/341 (19.6%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventPlaceboMemantine ER
FallInjury, poisoning and procedural complications5/3352/341
Cardiac Failure CongestiveCardiac disorders3/3350/341
Urinary tract infectionInfections and infestations3/3352/341
Hip fractureInjury, poisoning and procedural complications3/3350/341
Cardio-respiratory arrestCardiac disorders2/3350/341
PneumoniaInfections and infestations0/3352/341
Cerebrovascular accidentNervous system disorders0/3352/341
SyncopeNervous system disorders0/3352/341
BradycardiaCardiac disorders1/3351/341
Cardiac ArrestCardiac disorders1/3350/341
Most frequent other events
Most frequent other events
EventPlaceboMemantine ER
FallInjury, poisoning and procedural complications26/33519/341
Urinary tract infectionInfections and infestations24/33519/341
HeadacheNervous system disorders17/33519/341
DiarrhoeaGastrointestinal disorders13/33517/341

Baseline characteristics

Age, Customized
Age, Customized(participants)PlaceboMemantine ERTotal
<= 64 years263460
65-74 years7985164
75-84 years179176355
>= 85 years514697
Age Continuous
Age Continuous(years)PlaceboMemantine ERTotal
Mean76.8 ± 7.7676.2 ± 8.3576.5 ± 8.07
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMemantine ERTotal
Female243244487
Male9297189
Region of Enrollment
Region of Enrollment(participants)PlaceboMemantine ERTotal
United States8593178
Argentina158153311
Chile444690
Mexico484997
08

Study locations

83 sites
  • Forest Investigative Site 010
    Phoenix, Arizona 85004, United States
  • Forest Investigative Site 062
    Costa Mesa, California 92626, United States
  • Forest Investigative Site 050
    Fresno, California 93720, United States
  • Forest Investigative Site 024
    San Francisco, California 94118, United States
  • Forest Investigative Site 071
    Santa Ana, California 92705, United States
  • Forest Investigative Site 002
    Denver, Colorado 80262, United States
  • Forest Investigative Site 021
    Boca Raton, Florida 33486, United States
  • Forest Investigative Site 052
    Boynton Beach, Florida 33426, United States
  • Forest Investigative Site 070
    Delray Beach, Florida 33445, United States
  • Forest Investigative Site 065
    Fort Myers, Florida 33912, United States
  • Forest Investigative Site 043
    Hallandale Beach, Florida 33009, United States
  • Forest Investigative Site 044
    Hallandale Beach, Florida 33009, United States
  • Forest Investigative Site 001
    Miami, Florida 33137, United States
  • Forest Investigative Site 034
    North Miami, Florida 33161, United States
  • Forest Investigative Site 068
    Orlando, Florida 32806, United States
  • Forest Investigative Site 038
    Palm Beach Gardens, Florida 33410, United States
  • Forest Investigative Site 008
    Saint Petersburg, Florida 33709, United States
  • Forest Investigative Site 028
    Tampa, Florida 33617, United States
  • Forest Investigative Site 009
    Snellville, Georgia 30078, United States
  • Forest Investigative Site 069
    Joliet, Illinois 60435, United States
  • Forest Investigative Site 045
    Kalamazoo, Michigan 49048, United States
  • Forest Investigative Site 014
    Saint Loius, Missouri 63104, United States
  • Forest Investigative Site 064
    Long Branch, New Jersey 07742, United States
  • Forest Investigative Site 011
    Morristown, New Jersey 07960, United States
  • Forest Investigative Site 003
    New Brunswick, New Jersey 08903, United States
  • Forest Investigative Site 048
    Albany, New York 12205, United States
  • Forest Investigative Site 006
    Buffalo, New York 14215, United States
  • Forest Investigative Site 004
    White Plains, New York 10605, United States
  • Forest Investigative Site 027
    Centerville, Ohio 45459, United States
  • Forest Investigative Site 012
    Toledo, Ohio 43623, United States
  • Forest Investigative Site 020
    Portland, Oregon 97210, United States
  • Forest Investigative Site 032
    Greensburg, Pennsylvania 15601, United States
  • Forest Investigative Site 018
    Jenkintown, Pennsylvania 19046, United States
  • Forest Investigative Site 067
    East Providence, Rhode Island 02914, United States
  • Forest Investigative Site 041
    Austin, Texas 78757, United States
  • Forest Investigative Site 017
    San Antonio, Texas 78229, United States
  • Forest Investigative Site 013
    Richmond, Virginia 23229, United States
  • Forest Investigative Site 026
    Tacoma, Washington 98405, United States
  • Forest Investigative Site 103
    Banfield, Buenos Aires B1828CKR, Argentina
  • Forest Investigative Site 105
    La Plata, Buenos Aires B1900AVG, Argentina
  • Forest Investigative Site 123
    Lanus, Buenos Aires C1824IBR, Argentina
  • Forest Investigative Site 113
    Rosario, Santa Fe S2000DSV, Argentina
  • Forest Investigative Site 102
    Buenos Aires, 1419HDN, Argentina
  • Forest Investigative Site 118
    Buenos Aires, C1062ABF, Argentina
  • Forest Investigative Site 109
    Buenos Aires, C1117ABE, Argentina
  • Forest Investigative Site 104
    Buenos Aires, C1122AAJ, Argentina
  • Forest Investigative Site 108
    Buenos Aires, C1126AAB, Argentina
  • Forest Investigative Site 114
    Buenos Aires, C1181ACH, Argentina
  • Forest Investigative Site 106
    Buenos Aires, C1209AAB, Argentina
  • Forest Investigative Site 119
    Buenos Aires, C1405CNF, Argentina
  • Forest Investigative Site 122
    Buenos Aires, C1413FWO, Argentina
  • Forest Investigative Site 107
    Buenos Aires, C1419AHN, Argentina
  • Forest Investigative Site 111
    Buenos Aires, C1425AGP, Argentina
  • Forest Investigative Site 121
    Buenos Aires, C1425BPK, Argentina
  • Forest Investigative Site 115
    Buenos Aires, C1428AQK, Argentina
  • Forest Investigative Site 116
    Buenos Aires, C1428AQK, Argentina
  • Forest Investigative Site 112
    Cordoba, X5000ALB, Argentina
  • Forest Investigative Site 124
    Cordoba, X5004AOA, Argentina
  • Forest Investigative Site 110
    Mendoza, M5500HYF, Argentina
  • Forest Investigative Site 125
    Mendoza, M5504FMI, Argentina
  • Forest Investigative Site 120
    Santa Fe, S3000FWO, Argentina
  • Forest Investigative Site 308
    Coquimbo, Elqui, Chile
  • Forest Investigative Site 301
    Las Condes, Santiago, Chile
  • Forest Investigative Site 309
    Las Condes, Santiago, Chile
  • Forest Investigative Site 303
    Providencia, Santiago, Chile
  • Forest Investigative Site 310
    Providencia, Santiago, Chile
  • Forest Investigative Site 313
    Recoleta, Santiago, Chile
  • Forest Investigative Site 305
    San Ramon, Santiago, Chile
  • Forest Investigative Site 302
    Antofagasta, Chile
  • Forest Investigative Site 304
    Santiago, Chile
  • Forest Investigative Site 312
    Santiago, Chile
  • Forest Investigative Site 306
    Valdivia, Chile
  • Forest Investigative Site 212
    Saltillo, Coahuila 25000, Mexico
  • Forest Investigative Site 202
    Mexico City, Federal District 14000, Mexico
  • Forest Investigative Site 207
    Mexico City, Federal District 14050, Mexico
  • Forest Investigative Site 211
    Leon, Guanajuato 37000, Mexico
  • Forest Investigative Site 205
    Guadalajara, Jalisco 44610, Mexico
  • Forest Investigative Site 203
    Zapopan, Jalisco 45200, Mexico
  • Forest Investigative Site 208
    Monterrey, Nuevo Leon 44610, Mexico
  • Forest Investigative Site 204
    Monterrey, Nuevo Leon 64710, Mexico
  • Forest Investigative Site 213
    Culiacan, Sinaloa 80400, Mexico
  • Forest Investigative Site 206
    Aguascalientes, 20230, Mexico
  • Forest Investigative Site 210
    San Luis Potosi, 78090, Mexico
09

References and documents

Publications

  • Grossberg GT, Alva G, Hendrix S, Ellison N, Kane MC, Edwards J. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors. Alzheimer Dis Assoc Disord. 2018 Jul-Sep;32(3):173-178. doi: 10.1097/WAD.0000000000000261. PubMed 29771687 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Oct 2007 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2006
First posted
May 5, 2006
Start
Jun 2005
Primary completionActual
Oct 2007
CompletionActual
Jan 2008
Results first posted
Sep 16, 2010
Last update
Sep 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00322153
First posted
May 5, 2006
Start date
Jun 2005
Primary completion
Oct 2007
Completion
Jan 2008
Results posted
Sep 16, 2010
Last update
Sep 16, 2010

Study contacts

Stephen M Graham, PhD
study director · Forest Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion